Natixis Advisors L.P. Has $18.49 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Natixis Advisors L.P. grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 33.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 258,736 shares of the medical equipment provider’s stock after purchasing an additional 64,968 shares during the quarter. Natixis Advisors L.P.’s holdings in Hologic were worth $18,486,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Nordea Investment Management AB lifted its stake in Hologic by 4.5% in the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock valued at $113,077,000 after acquiring an additional 69,494 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in Hologic in the 4th quarter valued at about $1,057,000. Pathstone Family Office LLC grew its holdings in Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after purchasing an additional 4,542 shares during the period. Ontario Teachers Pension Plan Board increased its position in Hologic by 186.7% during the third quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after buying an additional 25,010 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its stake in Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 468 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on HOLX. Raymond James lifted their target price on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. UBS Group increased their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Friday. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $84.56.

Insider Activity

In related news, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

Hologic Stock Up 0.8 %

NASDAQ HOLX opened at $76.54 on Monday. The business has a fifty day moving average price of $76.13 and a two-hundred day moving average price of $73.09. The stock has a market capitalization of $17.97 billion, a PE ratio of 39.05, a PEG ratio of 2.55 and a beta of 1.01. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $86.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company earned $1.06 EPS. Hologic’s revenue for the quarter was down .8% on a year-over-year basis. Equities analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.